Beyond the Cancer Cell Itself For decades, cancer research focused almost exclusively on mutations in cancer cells. But it is now clear that the cellular neighborhood surrounding a tumor - the tumor microenvironment (TME) - plays an equally critical role in controlling whether a cancer grows, invades, or spreads. This review focuses on how the TME of hepatocellular carcinoma (HCC) specifically promotes tumor progression.
The Liver's Unique Cellular Landscape The liver is home to a rich mixture of specialized cells beyond hepatocytes: hepatic stellate cells (HSCs), Kupffer cells (liver-resident macrophages), sinusoidal endothelial cells, natural killer cells, and infiltrating immune cells. In HCC, each of these populations can be co-opted to create a pro-tumorigenic environment.
Cirrhosis as the Pre-Cancer Niche Over 90% of HCC arises in a liver with cirrhosis, a state of chronic inflammation and fibrosis. The cirrhotic microenvironment itself is already abnormal - with activated stellate cells, distorted sinusoids, and persistent inflammatory signaling - meaning that HCC does not create its microenvironment from scratch but exploits one that is already primed.
Therapeutic Opportunity Understanding the HCC microenvironment opens new avenues for treatment beyond targeting tumor cells directly. Strategies that block tumor-stroma crosstalk, normalize the vascular supply, or restore anti-tumor immune function could complement existing therapies.
From Fat Storage to Cancer Promoter Hepatic stellate cells (HSCs) normally store vitamin A and remain quiescent. In chronic liver injury - from viral hepatitis, alcohol, or metabolic disease - they activate into myofibroblast-like cells that produce collagen and fibrosis. In HCC, tumor-secreted signals keep HSCs in a persistently activated state that sustains the tumor.
TGF-beta as the Master Activator Transforming growth factor-beta (TGF-b) is the primary signal driving HSC activation. HCC cells secrete abundant TGF-b, which activates HSCs that then produce extracellular matrix proteins, growth factors, and more TGF-b in return - creating a self-reinforcing loop that promotes both fibrosis and tumor invasiveness.
HSCs Secrete Tumor-Promoting Growth Factors Activated HSCs release PDGF (platelet-derived growth factor), hepatocyte growth factor (HGF), and insulin-like growth factor (IGF), all of which directly stimulate HCC cell proliferation and survival. They also secrete matrix metalloproteinases (MMPs) that degrade the basement membrane and facilitate tumor cell migration.
Cancer-Associated Fibroblasts (CAFs) HSCs are the primary source of cancer-associated fibroblasts in HCC. CAFs remodel the extracellular matrix into a scaffold that physically supports tumor invasion and creates stiffened tissue that has been shown to directly activate cancer cell proliferation through mechanosensing pathways.
Kupffer Cells and Chronic Inflammation Kupffer cells are liver-resident macrophages that normally clear debris and pathogens. In chronic hepatitis, they become chronically activated, releasing pro-inflammatory cytokines such as TNF-alpha, IL-6, and reactive oxygen species. This persistent low-grade inflammation damages hepatocyte DNA, promoting malignant transformation over years to decades.
Regulatory T Cells Suppress Anti-Tumor Immunity HCC tumors are enriched in regulatory T cells (Tregs), which suppress the activity of cytotoxic T lymphocytes (CTLs) that would otherwise kill cancer cells. Tregs accomplish this through secretion of IL-10 and TGF-b and through direct contact-mediated suppression, effectively creating an immune-excluded tumor that evades detection.
Natural Killer Cells Are Impaired The liver normally contains a large population of natural killer (NK) cells that can kill abnormal cells without prior sensitization. In HCC, NK cell activity is significantly suppressed by TGF-b, prostaglandins, and other tumor-derived factors, depriving the immune system of a key innate defense mechanism.
Tumor-Infiltrating Lymphocytes Have Prognostic Value Despite immune suppression, the density and composition of tumor-infiltrating lymphocytes (TILs) correlates with HCC prognosis. Tumors with high CTL and low Treg infiltration show better outcomes, establishing TIL profiling as a potential biomarker and identifying immune checkpoint blockade as a rational therapeutic strategy.
HCC Is a Highly Vascular Tumor Hepatocellular carcinoma is one of the most vascularized solid tumors. HCC cells rapidly outgrow their blood supply and respond by secreting vascular endothelial growth factor (VEGF) and angiopoietins, which stimulate sinusoidal endothelial cells to form new blood vessels (angiogenesis) that feed the expanding tumor.
VEGF as the Key Angiogenic Driver VEGF-A is the dominant pro-angiogenic factor in HCC and is often amplified at the genomic level in a subset of tumors. VEGF signaling through its receptor VEGFR-2 promotes endothelial cell proliferation, migration, and tube formation. This pathway is the primary target of sorafenib, the main systemic drug approved for advanced HCC.
Abnormal Vessels Create a Hypoxic Core Despite abundant angiogenesis, HCC-associated vessels are structurally abnormal - leaky, tortuous, and poorly organized. This creates paradoxical hypoxia within the tumor core, which further stimulates VEGF production in a positive feedback loop and promotes the aggressive, invasive phenotype associated with hypoxia-inducible factors (HIFs).
Endothelial-Mesenchymal Crosstalk Sinusoidal endothelial cells in HCC also engage in bidirectional crosstalk with tumor cells, secreting factors like angiopoietin-2 that promote invasion, and receiving signals from tumor cells that alter their gene expression. This crosstalk represents an underexplored layer of TME regulation.
The ECM as a Physical Barrier and Signaling Platform The extracellular matrix (ECM) surrounding HCC cells is not merely a scaffold. ECM proteins such as fibronectin, laminin, and type I collagen bind directly to cancer cell surface integrins and activate proliferative, anti-apoptotic, and migratory signaling cascades.
MMPs Break Down Barriers to Invasion Matrix metalloproteinases (MMPs) - particularly MMP-2, MMP-9, and MMP-14 - are highly upregulated in HCC and its surrounding stroma. These enzymes degrade structural ECM components, physically clearing the way for tumor cell migration into blood vessels and adjacent liver parenchyma.
TIMPs: The Natural Brakes on MMP Activity Tissue inhibitors of metalloproteinases (TIMPs) naturally counterbalance MMPs. In aggressive HCC, the ratio of MMPs to TIMPs is shifted strongly toward MMP activity, and low TIMP expression is associated with worse prognosis, intrahepatic metastasis, and vascular invasion.
Stiffness Drives Malignant Behavior Liver stiffness, measurable by elastography as a clinical tool, reflects the degree of fibrosis. At the molecular level, increased ECM stiffness activates mechanosensory pathways including YAP/TAZ, which promote cancer cell stemness, resistance to apoptosis, and chemotherapy resistance - connecting the physical properties of the TME to the molecular behavior of tumor cells.
Sorafenib Targets Tumor-Stroma Crosstalk Sorafenib, the standard-of-care for advanced HCC, inhibits VEGFR and PDGFR signaling - receptors important not only on cancer cells but also on activated stellate cells and endothelial cells. Its antitumor effects likely reflect both direct effects on HCC cells and disruption of stroma-tumor signaling.
TGF-beta Inhibition as a Strategy Given TGF-b's central role in both activating stellate cells and suppressing anti-tumor immunity, TGF-b pathway inhibitors are under active clinical investigation in HCC. The challenge is that TGF-b also has tumor-suppressive functions in early stages, requiring careful patient selection.
Immune Checkpoint Blockade Agents targeting PD-1/PD-L1 and CTLA-4 checkpoints have shown activity in HCC, particularly in combination with anti-VEGF therapies. The rationale is that normalizing the tumor vasculature may increase immune cell penetration into the tumor while checkpoint blockade restores their killing capacity.
Gene Expression Signatures of the Microenvironment Several published gene expression signatures capture the state of the HCC microenvironment and stratify patients by prognosis. Signatures reflecting hepatic stellate cell activation, immune infiltration, or hypoxic stress can identify patient subgroups most likely to benefit from specific TME-targeting approaches.
Heterogeneity of the Microenvironment Just as HCC tumors themselves are molecularly heterogeneous, so too are their microenvironments. Single-cell sequencing and spatial transcriptomics are beginning to reveal the fine-grained architecture of cell types and communication networks within individual HCC tumors - information that bulk gene expression studies cannot provide.
Pre-Malignant Microenvironment as a Prevention Target If the cirrhotic microenvironment primes the liver for HCC development, could treating the microenvironment before cancer arises reduce HCC incidence? Anti-fibrotic agents and immune modulators are being explored in this context.
Biomarkers Predicting Response to TME-Targeting Therapies Not all HCC patients respond to sorafenib or immunotherapy. Identifying biomarkers - whether from tumor biopsies, liquid biopsies (circulating tumor DNA), or imaging - that predict which patients have the microenvironmental features most likely to respond to each therapy is a critical unmet need.
Combination Strategies Given the multiple parallel pro-tumorigenic circuits in the HCC microenvironment, single-agent approaches may be insufficient. Rational combination strategies that simultaneously target angiogenesis, immune suppression, and stellate cell activation are being explored in clinical trials, guided by the mechanistic insights reviewed in this paper.